BTIG Maintains Buy on Solventum, Raises Price Target to $95
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
BTIG analyst Ryan Zimmerman maintains Solventum (NYSE:SOLV) with a Buy and raises the price target from $91 to $95.
BTIG analyst Ryan Zimmerman maintains Solventum (NYSE:SOLV) with a Buy and raises the price target from $91 to $95.